Epigenetic‐based therapy in allogenic hematopoietic stem cell transplantation: Novel opportunities for personalized treatment

Abstract

Current management of patients undergoing allogeneic hematopoietic stem cell transplantation (allo‐HSCT) lacks immunosuppressant drugs able to block the host immune response toward the graft antigens. Novel treatments may include epigenetic compounds (epidrugs) some of which have been yet approved by the Food and Drugs Administration for the treatment of specific blood malignancies. The most investigated in clinical trials for allo‐HSCT are DNA demethylating agents (DNMTi), such as azacitidine (Vidaza) and decitabine (Dacogen) as well as histone deacetylases inhibitors (HDACi), such as vorinostat (Zolinza) and panobinostat (Farydak). Indeed, azacitidine monotherapy before allo‐HSCT may reduce the conventional chemotherapy‐related complications, whereas it may reduce relapse risk and death after allo‐HSCT. Besides, a decitabine‐containing conditioning regimen could protect against graft versus host disease (GVHD) and respiratory infections after allo‐HSCT. Regarding HDACi, the addition of vorinostat and panobinostat to the conditioning regimen after allo‐HSCT seems to reduce the incidence of acute GVHD. Furthermore, panobinostat alone or in combination with low‐dose decitabine may reduce the relapse rate in high‐risk patients with acute myeloid leukemia patients after allo‐HSCT. We discuss the phase 1 and 2 clinical trials evaluating the possible beneficial effects of repurposing specific epidrugs which may guide personalized therapy in the setting of allo‐HSCT.